Correction: Brolucizumab—early real-world experience: BREW study (Eye, (2021), 35, 4, (1045-1047), 10.1038/s41433-020-1111-x)

Abstract

Since online publication of this article, the authors became aware of two errors in the text of the manuscript: 1. Page 1 Paragraph 1, an incorrect approval date was inserted. The correct sentence is provided below: Brolucizumab (Beovu, Novartis, Basel, Switzerland) is the newest anti-vascular endothelial growth factor (anti-VEGF) drug. lt was approved for the treatment of neovascular age-related macular degeneration (nAMD) by the US-FDA on October 7, 2019, followed by the European Commission’s approval for use in the European Union on February 13, 2020. 2. Page 2 Paragraph 1, an incorrect percentage was provided. The correct sentence is provided below: Pigment epithelial detachment (PED) was present in 31 eyes (73.8%) at baseline and resolved in 2 eyes (6.4%), was reduced in 13 eyes (41.9%\, and did not show any change in 16 eyes (51.6%) (Fig. 1). The authors apologise for any inconvenience caused.